Calidi Biotherapeutics (CLDI) said Thursday it has priced its offering of about 4.44 million shares at $1.69 apiece, targeting gross proceeds of $7.5 million.
The company intends to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.
Shares slumped 36% intraday.
Bragg Gaming (BRAG) reported higher Q3 revenue and concluded a strategic review, saying that ongoing execution of its strategy best option to maximize shareholder value. The company also said it is "currently tracking to the lower end of guidance" for 2024.
Shares sank 27% as intraday trading volume jumped to over 461,000 versus a daily average of about 32,000.
Chardan downgraded Allurion Technologies (ALUR) to neutral from buy following Q3 results released Wednesday.
Shares of Allurion sank 25% as intraday trading volume climbed to more than 684,000 from a daily average of roughly 186,000.
Price: 2.18, Change: -1.20, Percent Change: -35.50
Comments